Aliskiren/amlodipine/hydrochlorothiazide

The drug combination aliskiren/amlodipine/hydrochlorothiazide (INNs, trade name Amturnide) is an antihypertensive approved in the United States on 21 December 2010.[1][2]

Aliskiren/amlodipine/hydrochlorothiazide
Combination of
AliskirenRenin inhibitor
AmlodipineCalcium channel blocker
HydrochlorothiazideDiuretic
Clinical data
Trade namesAmturnide
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
PubChem CID
KEGG
Chemical and physical data
FormulaC57H86Cl2N8O15S2
Molar mass1258.38 g·mol−1
3D model (JSmol)
  (verify)

References
  1. Amturnide approval letter. U.S. Food and Drug Administration (FDA).
  2. "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020. Lay summary (PDF).


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.